摘要
Abstract
OBJECTIVE:To observe therapeutic efficacy and safety of prednisone acetate combined with leflunomide in the treatment of IgA nephropathy. METHODS:80 patients with IgA nephropathy were randomly divided into observation group and control group,with 40 cases in each group. Control group was given prednisone acetate 1.0 mg/kg,qd,6 weeks later,decreasing gradually,decreasing to 0.5 mg/kg in 12th week;observation group was additionally given leflunomide 50 mg,qd,3 days later de-creasing to 20 mg. Both groups were given 3 months of treatment. Clinical efficacy,24 h urinary protein quantification,Scr and BUN levels were observed in 2 groups after treatment,and ADR were recorded during treatment. RESULTS:Total effective rate of observation group(95.0%)was significantly higher than that of control group(75.0%),with statistical significance(P<0.05). Af-ter treatment,24 h urinary protein quantification,Scr and BUN levels of observation group were significantly lower than those of control group,with statistical significance(P<0.05). The incidence of ADR in observation group(0)was significantly lower than in control group(7.5%),with statistical significance(P<0.05). CONCLUSIONS:Prednisone acetate combined with leflunomide has significant effect on IgA nephropathy,and will not increase the occurrence of ADR.关键词
醋酸泼尼松/来氟米特/免疫球蛋白A肾病/安全性Key words
Prednisone acetate/Leflunomide/IgA nephropathy/Effectiveness分类
医药卫生
